Parmax Pharma seller Pradeep Gosalia disposes 300,000 shares, cutting stake to 0.07%

What Parmax Pharma announced

Parmax Pharma Ltd (BSE: 540359) recorded a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing, submitted on 22 June 2026 by shareholder Pradeep Ramniklal Gosalia, details the disposal of 300,000 equity shares of the company. The transaction reduces Gosalia’s holding from 302,714 shares (8.09 % of total voting capital) to 2,714 shares (0.07 %).

The sale was effected on 18 June 2026 by way of a transfer pursuant to a Share Purchase Agreement (SPA) between Rupa Sunil Shah and Abhay Chinubhai Shah. The filing was logged with BSE on 23 June 2026.

Details of the share disposal

• Seller: Pradeep Ramniklal Gosalia (non‑promoter, not part of any promoter group).
• Shares sold: 300,000 equity shares carrying voting rights, representing 8.02 % of Parmax Pharma’s total share capital.
• Pre‑sale holding: 302,714 shares (8.09 %).
• Post‑sale holding: 2,714 shares (0.07 %).
• Mode of acquisition/sale: Off‑market transfer under a Share Purchase Agreement between Rupa Sunil Shah and Abhay Chinubhai Shah.
• Date of transaction: 18 June 2026.
• Total equity share capital of Parmax Pharma: 3,741,300 shares, face value Rs 10 per share, amounting to Rs 374.13 lakh. The capital structure remains unchanged after the transaction.

No encumbrances, pledges, or convertible securities were involved in the disposal. The filing confirms that the seller did not hold any voting rights other than through shares, nor any warrants or convertible instruments.

Regulatory filing under SEBI Regulation 29(2)

Regulation 29(2) requires any person who acquires or disposes of shares that would affect the shareholding percentage of a target company to disclose the transaction to the stock exchange. The purpose is to ensure transparency for investors and to monitor potential changes in control.

In this case, the seller’s post‑sale holding falls well below the 1 % threshold that typically triggers additional disclosure obligations, but the filing remains mandatory because the transaction involved more than 5 % of the total voting capital before the disposal.

Key facts at a glance

Why this matters for investors

The disclosure does not alter Parmax Pharma’s capital structure or dilute existing shareholders, as the total number of shares remains unchanged. However, it signals a significant reduction in the stake of a large non‑promoter shareholder. Investors may view the sale as a routine portfolio rebalancing, but the fact that the shares were transferred to parties identified in the SPA could be of interest if those parties become active shareholders.

Because the seller’s post‑sale holding is now below 1 %, any future transactions by Gosalia are unlikely to trigger further mandatory disclosures unless his stake rises again. The filing also confirms that there are no encumbrances or pending convertible instruments that could affect future share dilution.

Conclusion

Parmax Pharma Ltd recorded a SEBI 29(2) filing on 22 June 2026 showing that shareholder Pradeep Ramniklal Gosalia sold 300,000 shares, reducing his ownership from 8.09 % to 0.07 %. The off‑market transfer was executed under a Share Purchase Agreement between Rupa Sunil Shah and Abhay Chinubhai Shah. The company’s share capital remains unchanged, and no further regulatory approvals are pending for this transaction.